ArticleDrug design, development and therapy2026
Optimizing Colistin Sulfate Dosing in Severe Infections: A Population Pharmacokinetic Model-Guided Approach.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colistin sulfate is effective against carbapenem-resistant Gram-negative bacilli but has a narrow therapeutic window, large pharmacokinetic variability, and high resistance risk. Clinical data remain limited, and individualized dosing guidance is urgently needed. This study aims to establish a population pharmacokinetic (PPK) model to optimize and guide precise individualized dosing of colistin sulfate in critically ill patients. Methods: Critically ill patients with confirmed CRO infections receiving intravenous colistin sulfate at the Second Hospital of Hebei Medical University from June 2021 to June 2023 were enrolled. A PPK model was developed using NONMEM. Goodness-of-fit (GOF) diagnostics and visual predictive check (VPC) were used to evaluate the predictive performance of the model, while the bootstrap method (BS) was used to assess its stability. Clinical efficacy, microbiological efficacy, and adverse reactions were assessed. Monte Carlo simulation calculated the probability of target attainment (PTA) across different MICs and renal function strata to optimize the colistin sulfate dosing regimen. Results: Among 51 patients, clinical efficacy was 60.78% (31/51), bacterial clearance 52.94% (27/51), and nephrotoxicity 3.92% (2/51). The PPK model included 123 concentration points (range: 0.12-4.40 mg/L).A one-compartment linear elimination model best described the PK profile. Typical values of clearance (CL) and volume of distribution (V) were 1.66 L/h and 10.10 L, respectively. Creatinine clearance (CrCL) was identified as a significant covariate affecting CL. Monte Carlo simulation showed that the recommended regimen achieved PTA ≥90% only when MIC ≤0.5 μg/mL with normal renal function. When MIC ≥1 μg/mL, there was a risk of insufficient exposure in patients with normal renal function. When MIC ≥2 μg/mL, no dosing regimen achieved PTA ≥90%. Conclusion: Renal function significantly impacts colistin sulfate clearance. Dose adjustment based on CrCL is necessary. The standard dosing regimen risks underexposure in patients with normal renal function and MIC ≥1 mg/L. Off-label high-dose regimens should be considered in such cases to ensure adequate drug exposure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.